← Back to patent-cliff list
CAS 55686-22-1
N,N-Dihydroxymethyl-t-butylamine
Codes：Rifampicin-011
Application context (from source-drug indications)
结核分枝杆菌感染盐酸乙胺丁醇/利福平/异烟肼结核分枝杆菌感染利福平麻风分枝杆菌感染利福平肺结核利福平脑膜炎球菌性脑膜炎利福平新型冠状病毒感染利福平呼吸道病毒感染利福平
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ethambutol Hydrochloride/Rifampicin/IsoniazidEthambutol Hydrochloride/Rifampicin/Isoniazid | Tier C — Watch / trade | - |
| RifampicinRifampicin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-Acetoxy-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-1,11-dione→(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-17-(Acetyloxy)-3-tert-butyl-7,19,21-trihydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-10,11-dihydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-3-ium-6-olate→Acetic acid (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ester→4-Methylpiperazin-1-amine
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→2-Methylpropan-2-amine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-tert-Butyl-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-3,8,10,16,18,20,22,26-octamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-3-[2-(morpholin-4-yl)ethyl]-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-(1-Ethylpiperidin-3-yl)-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→4-Methylpiperazin-1-amine→N-Methylpiperazine
(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-Acetoxy-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-1,11-dione→(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-17-(Acetyloxy)-3-tert-butyl-7,19,21-trihydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-10,11-dihydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-3-ium-6-olate→Acetic acid (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-8-formyl-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ester→4-Methylpiperazin-1-amine
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17-Trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27,29-tetraoxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),2,4,9,19,21,25-heptaen-13-yl acetate→N,N-Dihydroxymethyl-t-butylamine→2-Methylpropan-2-amine→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-tert-Butyl-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-3,8,10,16,18,20,22,26-octamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-6,7,19,21-Tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-3-[2-(morpholin-4-yl)ethyl]-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→(10S,13E,15S,16R,17S,18R,19R,20R,21S,22S,23E,25Z)-3-(1-Ethylpiperidin-3-yl)-6,7,19,21-tetrahydroxy-15-methoxy-8,10,16,18,20,22,26-heptamethyl-11,27-dioxo-3,4,10,11-tetrahydro-2H-10,5-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[2,1-e][1,3]oxazin-17-yl acetate→4-Methylpiperazin-1-amine→N-Methylpiperazine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.